Your session is about to expire
← Back to Search
Ultra-Hypo vs Conventional IMRT for Prostate Cancer (PCS-XI Trial)
PCS-XI Trial Summary
This trial compares the effectiveness of two radiation treatments for prostate cancer with the aim of finding which one is best.
PCS-XI Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.PCS-XI Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of autoimmune diseases like Lupus.I have a history of inflammatory bowel disease.My cancer has spread to other parts of my body.My cancer has not spread to distant parts of my body.My condition is classified as intermediate to very high risk.My cancer has a risk of spreading to lymph nodes needing pelvic radiation.My prostate cancer is confirmed by a tissue examination.I have had radiation therapy to my pelvic area before.I can make my own medical decisions.My prostate symptoms are severe, even with medication.
- Group 1: standard of care fractionation (SOC)
- Group 2: ultra hypo fractionation radiation therapy (UHF)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Am I eligible to sign up for this clinical examination?
"To be accepted, 500 people aged between 18 and 95 who have been diagnosed with prostate cancer will need to apply."
Is it possible for individuals aged 50 or more to participate in this experiment?
"This clinical trial can only accept applicants between the ages of 18 to 95. For younger and elderly individuals, there are 67 trials open for those under 18 and 1343 studies available for people over 65."
What is the approximate size of this clinical research's recruitment?
"Affirmative. According to information accessible on clinicaltrials.gov, this research project is presently looking for volunteers and was posted online on the 1st of September 2022; the data has been recently updated on April 7th 2023. This investigation needs 500 individuals across a single medical facility to participate."
Is enrollment still ongoing for this research project?
"Indeed, the information posted on clinicaltrials.gov confirms that this medical research is recruiting test subjects. It was first listed online on September 1st 2022 and has gone through subsequent revisions as recently as April 7th 2023. The study requires 500 participants to be enrolled at one location."
What is the overarching objective of this research trial?
"TerSera Therapeutics LLC, the trial sponsor, is assessing primary outcomes every 3 months for 1 year. Specifically, they are conducting a non-inferiority analysis of late change in genito-urinary (GU) toxicities induced. Additionally, there will be secondary endpoints such as comparing 5 years Disease Free Survival and Metastasis Free Survival between two groups through a non-inferiority approach as well as evaluating five years Overall Survival with an intent to measure any lack of inferiority."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger